Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2025)

Xeris Biopharma Holdings' Net Margin history spans 6 years, with the latest figure at 12.91% for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 2142.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2719.0%, and an annual FY2025 reading of 0.19%, up 2719.0% over the prior year.
  • Net Margin for Q4 2025 was 12.91% at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • The five-year high for Net Margin was 12.91% in Q4 2025, with the low at 308.95% in Q2 2021.
  • Average Net Margin over 5 years is 82.62%, with a median of 42.86% recorded in 2022.
  • Year-over-year, Net Margin crashed -6495bps in 2021 and then skyrocketed 20548bps in 2022.
  • Tracing XERS's Net Margin over 5 years: stood at 237.02% in 2021, then soared by 84bps to 39.01% in 2022, then increased by 23bps to 30.16% in 2023, then soared by 72bps to 8.51% in 2024, then soared by 252bps to 12.91% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Net Margin are 12.91% (Q4 2025), 0.83% (Q3 2025), and 2.7% (Q2 2025).